Published in Arthritis Rheum on October 01, 1984
Rheumatoid factor and antibodies to cyclic citrullinated peptides are associated with severe extra-articular manifestations in rheumatoid arthritis. Ann Rheum Dis (2006) 1.15
Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol (2014) 1.10
Formation of soluble immune complexes by complement in sera of patients with various hypocomplementemic states. Difference between inhibition of immune precipitation and solubilization. J Clin Invest (1985) 1.04
Circulating immune complexes associated with decreased complement-mediated inhibition of immune precipitation in sera from patients with bacterial endocarditis. Clin Exp Immunol (1986) 0.84
Reduction of the complement activation capacity of soluble IgG aggregates and immune complexes by IgM-rheumatoid factor. Immunology (1985) 0.83
Complement mediated inhibition of immune precipitation in rheumatoid arthritis: studies on interaction of heat aggregated IgG with IgM rheumatoid factor. Ann Rheum Dis (1988) 0.79
Mechanism of action of an inhibitor of complement-mediated prevention of immune precipitation. Immunology (1990) 0.76
Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis (2002) 20.48
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost (2006) 16.11
Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum (1993) 7.14
The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum (1996) 6.88
Signals regulating hepatitis B surface antigen transcription. Nature (1983) 5.02
Replication strategy of human hepatitis B virus. J Virol (1987) 4.42
Association between polyarteritis and Australia antigen. Lancet (1970) 4.32
Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum (2001) 4.06
Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis (1996) 3.68
Hepatitis B virus transcription in the infected liver. EMBO J (1984) 3.44
EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis (2007) 3.32
Measles viruses with altered envelope protein cytoplasmic tails gain cell fusion competence. J Virol (1998) 3.27
New susceptibility locus for rheumatoid arthritis suggested by a genome-wide linkage study. Proc Natl Acad Sci U S A (1998) 3.14
Measles virus spread and pathogenesis in genetically modified mice. J Virol (1998) 2.84
Cloned HBV DNA causes hepatitis in chimpanzees. Nature (1982) 2.80
Ilizarov treatment of tibial nonunions with bone loss. Clin Orthop Relat Res (1989) 2.71
Altered transcription of a defective measles virus genome derived from a diseased human brain. EMBO J (1987) 2.67
Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis (2009) 2.61
Structure of the FMDV translation initiation site and of the structural proteins. Nucleic Acids Res (1983) 2.58
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
Biased hypermutation of viral RNA genomes could be due to unwinding/modification of double-stranded RNA. Cell (1989) 2.54
EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis (2010) 2.52
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis (2001) 2.49
A matrix-less measles virus is infectious and elicits extensive cell fusion: consequences for propagation in the brain. EMBO J (1998) 2.48
Association between hepatitis C virus and mixed cryoglobulinemia [see comment]. Clin Exp Rheumatol (1992) 2.43
The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis (2010) 2.38
Retracted Infectious measles virus from cloned cDNA. EMBO J (1990) 2.36
Extrahepatic manifestations of Hepatitis C Virus infection: a general overview and guidelines for a clinical approach. Dig Liver Dis (2006) 2.24
Infectious hepatitis B virus from cloned DNA of known nucleotide sequence. Proc Natl Acad Sci U S A (1985) 2.20
Exacerbation of peripheral neuropathy during alpha-interferon therapy in a patient with mixed cryoglobulinemia and hepatitis B virus infection. J Rheumatol (1996) 2.11
Murine monoclonal anti-DNA antibodies bind directly to glomerular antigens and form immune deposits. J Immunol (1987) 2.09
Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. Am J Med (1995) 2.07
The European Community Study Group on diagnostic criteria for Sjögren's syndrome. Sensitivity and specificity of tests for ocular and oral involvement in Sjögren's syndrome. Ann Rheum Dis (1994) 2.03
Misdiagnosis in fibromyalgia: a multicentre study. Clin Exp Rheumatol (2012) 2.02
Association of early-onset Alzheimer's disease with an interleukin-1alpha gene polymorphism. Ann Neurol (2000) 1.99
A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum (2012) 1.96
Preferential initiation at the second AUG of the measles virus F mRNA: a role for the long untranslated region. Virology (1995) 1.96
Affinity purified anti-cardiolipin and anti-DNA antibodies. J Clin Lab Immunol (1985) 1.92
Interaction of measles virus glycoproteins with the surface of uninfected peripheral blood lymphocytes induces immunosuppression in vitro. Proc Natl Acad Sci U S A (1996) 1.89
The hemagglutinin of canine distemper virus determines tropism and cytopathogenicity. J Virol (2001) 1.88
Measles virus envelope glycoproteins hetero-oligomerize in the endoplasmic reticulum. J Biol Chem (2001) 1.87
Assessment of disease severity and prognosis. Clin Exp Rheumatol (2003) 1.86
Expression of defective measles virus genes in brain tissues of patients with subacute sclerosing panencephalitis. J Virol (1986) 1.84
Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood (2001) 1.84
A novel expression selection approach allows precise mapping of the hepatitis B virus enhancer. Nucleic Acids Res (1985) 1.82
Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood (2001) 1.82
Retracted Functional and nonfunctional measles virus matrix genes from lethal human brain infections. J Virol (1991) 1.82
Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Ann Rheum Dis (2004) 1.80
Expression of hepatitis B antigens with a simian virus 40 vector. J Virol (1984) 1.80
Undifferentiated connective tissue diseases: the clinical and serological profiles of 91 patients followed for at least 1 year. Lupus (1998) 1.79
Measles virus phosphoprotein retains the nucleocapsid protein in the cytoplasm. Virology (1991) 1.77
Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain? J Neuroimmunol (2000) 1.76
Chimeric measles viruses with a foreign envelope. J Virol (1998) 1.75
Central nervous system involvement in systemic lupus erythematosus patients without overt neuropsychiatric manifestations. Lupus (1999) 1.70
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis (2009) 1.69
Intravenous cyclophosphamide therapy for systemic sclerosis. A single-center experience and review of the literature with pooled analysis of lung function test results. Clin Exp Rheumatol (2004) 1.68
Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol (1999) 1.68
Clinical and morphological features of kidney involvement in primary Sjögren's syndrome. Nephrol Dial Transplant (2001) 1.67
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum (2008) 1.66
Altered adrenal sensitivity to angiotensin II in low-renin essential hypertension. Hypertension (1999) 1.64
Human anticardiolipin monoclonal autoantibodies cause placental necrosis and fetal loss in BALB/c mice. Arthritis Rheum (1998) 1.63
Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford) (2002) 1.61
Anticardiolipin antibodies: occurrence in Behçet's syndrome. Ann Rheum Dis (1984) 1.61
Systemic lupus erythematosus and pregnancy: a prospective study. Clin Exp Rheumatol (1993) 1.60
Detection of an element of the SV40 late promoter in vectors used for expression studies in COS cells. EMBO J (1983) 1.57
Restricted expression of T cell receptor V beta but not V alpha genes in rheumatoid arthritis. Eur J Immunol (1991) 1.55
Enhanced activity of sodium-lithium countertransport in patients with cardiac syndrome X: a potential link between cardiac and metabolic syndrome X. J Am Coll Cardiol (1998) 1.51
Cell entry by measles virus: long hybrid receptors uncouple binding from membrane fusion. J Virol (1996) 1.51
Alpha-enolase is a renal-specific antigen associated with kidney involvement in mixed cryoglobulinemia. Clin Exp Rheumatol (1998) 1.50
Prevalence of anticardiolipin antibodies in coronary artery disease. Am J Cardiol (1990) 1.49
Accumulated measles virus mutations in a case of subacute sclerosing panencephalitis: interrupted matrix protein reading frame and transcription alteration. Virology (1986) 1.49
Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia. Arthritis Rheum (1991) 1.49
Lymphatic dissemination and comparative pathology of recombinant measles viruses in genetically modified mice. J Virol (2000) 1.48
HLA-DR antigens and anticardiolipin antibodies in northern Italian systemic lupus erythematosus patients. Arthritis Rheum (1988) 1.48
Shrinking lung in primary Sjögren's syndrome. Arthritis Rheum (1999) 1.47
Endothelial cells as target for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation. Arthritis Rheum (1997) 1.45
Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol (2000) 1.44
Electrocardiographic abnormalities in infants born from mothers with autoimmune diseases--a multicentre prospective study. Rheumatology (Oxford) (2007) 1.44
Transfer of experimental antiphospholipid syndrome by bone marrow cell transplantation. The importance of the T cell. Arthritis Rheum (1995) 1.44
Anti-Sm and anti-RNP antibodies. Autoimmunity (2005) 1.43
Cytokine patterns in fibromyalgia and their correlation with clinical manifestations. Clin Exp Rheumatol (2007) 1.41
Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. Lupus (2002) 1.41
Cortisol secretion in patients on simvastatin. Lancet (1990) 1.40
Vasculitis in association with Australia antigen. J Exp Med (1971) 1.40